MNMD vs. TLRY, CRON, USNA, CGC, BTMD, ACB, CDXC, MDWD, FTLF, and BGXX
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Tilray (TLRY), Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), MediWound (MDWD), FitLife Brands (FTLF), and Bright Green (BGXX). These companies are all part of the "medicinals & botanicals" industry.
Tilray (NASDAQ:TLRY) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
9.4% of Tilray shares are held by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 0.7% of Tilray shares are held by company insiders. Comparatively, 2.3% of Mind Medicine (MindMed) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Mind Medicine (MindMed) had 1 more articles in the media than Tilray. MarketBeat recorded 13 mentions for Mind Medicine (MindMed) and 12 mentions for Tilray. Tilray's average media sentiment score of 0.46 beat Mind Medicine (MindMed)'s score of 0.31 indicating that Mind Medicine (MindMed) is being referred to more favorably in the news media.
Mind Medicine (MindMed) has lower revenue, but higher earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.
Mind Medicine (MindMed) has a net margin of 0.00% compared to Mind Medicine (MindMed)'s net margin of -43.98%. Mind Medicine (MindMed)'s return on equity of -2.68% beat Tilray's return on equity.
Tilray currently has a consensus price target of $2.71, indicating a potential upside of 50.46%. Mind Medicine (MindMed) has a consensus price target of $19.00, indicating a potential upside of 115.91%. Given Tilray's stronger consensus rating and higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Tilray.
Tilray has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500.
Tilray received 408 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 90.70% of users gave Mind Medicine (MindMed) an outperform vote while only 59.28% of users gave Tilray an outperform vote.
Summary
Mind Medicine (MindMed) beats Tilray on 13 of the 18 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
